Table of Content

Part 1. Introduction
1.1 Market Definition
1.2 Key Benefit
1.3 Market Segment
Part 2. Methodology
2.1 Primary
2.2 Secondary
Part 3. Executive Summary

Part 4. Market Overview
4.1 Introduction
4.2 Market Size and Forecast
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.4 Impact of COVID-19 Pandemic

Part 5. Global Market for Irritable Bowel Syndrome Treatment by Type
5.1 Ibs With Constipation (Ibs-C)
5.1.1 Market Size and Forecast
5.2 Ibs With Diarrhea (Ibs-D)
5.2.1 Market Size and Forecast
5.3 Mixed-Presentation Ibs (Ibs-M)
5.3.1 Market Size and Forecast

Part 6. Global Market for Irritable Bowel Syndrome Treatment by Product
6.1 Eluxadoline
6.1.1 Market Size and Forecast
6.2 Linaclotide
6.2.1 Market Size and Forecast
6.3 Lubiprostone
6.3.1 Market Size and Forecast
6.4 Rifaximin
6.4.1 Market Size and Forecast
6.5 Others
6.5.1 Market Size and Forecast

Part 7. Global Market for Irritable Bowel Syndrome Treatment by Distribution Channel
7.1 Drug Stores And Retail Pharmacies
7.1.1 Market Size and Forecast
7.2 Hospitals’ Pharmacies
7.2.1 Market Size and Forecast
7.3 Online Pharmacies
7.3.1 Market Size and Forecast
7.4 Others
7.4.1 Market Size and Forecast

Part 8. Global Market for Irritable Bowel Syndrome Treatment by Region
8.1 Asia-Pacific
8.1.1 Market Size and Forecast
8.2 Europe
8.2.1 Market Size and Forecast
8.3 North America
8.3.1 Market Size and Forecast
8.4 Middle East And Africa (Mea)
8.4.1 Market Size and Forecast
8.5 South America
8.5.1 Market Size and Forecast

Part 9. Key Competitor Profiles
9.1 Abbott Laboratories
9.2 Allergan plc
9.3 Ardelyx, Inc.
9.4 Astellas Pharma Inc.
9.5 AstraZeneca plc
9.6 GlaxoSmithKline plc
9.7 Johnson & Johnson
9.8 Novartis AG
9.9 The Takeda Pharmaceutical Company Limited
*LIST IS NOT EXHAUSTIVE

Part 10. Patent Analysis
10.1 Patent Statistics
10.2 Regional Analysis
10.3 Trends Analysis

DISCLAIMER
ABOUT GEN CONSULTING COMPANY